Literature DB >> 24632282

Current treatment of in-stent restenosis.

Fernando Alfonso1, Robert A Byrne2, Fernando Rivero3, Adnan Kastrati2.   

Abstract

Management of patients with in-stent restenosis (ISR) remains an important clinical problem. Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment of DES-ISR is particularly challenging. ISR mainly results from aggressive neointimal proliferation, but recent data also suggest that neoatherosclerosis may play an important pathophysiological role. Intracoronary imaging provides unique insights to unravel the underlying substrate of ISR and may be used to guide repeated interventions. In this paper, we systematically reviewed clinical trial data with currently available therapeutic modalities, including DES and drug-coated balloons, in patients presenting with ISR within bare-metal stents or DES.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bare-metal stents; drug-coated balloons; drug-eluting stents; in-stent restenosis; intravascular ultrasound; neoatherosclerosis; optical coherence tomography

Mesh:

Year:  2014        PMID: 24632282     DOI: 10.1016/j.jacc.2014.02.545

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  95 in total

1.  Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.

Authors:  In Sook Kang; Islam Shehata; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Heart Vessels       Date:  2015-09-04       Impact factor: 2.037

2.  Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety.

Authors:  Fernando Alfonso; Fernando Rivero
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  In-stent restenosis: local drug delivery with a stent or balloon?

Authors:  Matias B Yudi; Ron Waksman; Andrew E Ajani
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

4.  Optimal interventional strategy for the treatment of coronary in-stent restenosis.

Authors:  Ji'e Yang; Wahafu Mamuti; Feng Zhang
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

5.  Comparison of 12-month angiographic outcomes between repeat drug-eluting stent implantation and drug-coated balloon treatment for restenotic lesion caused by stent fracture.

Authors:  Yasunari Sakamoto; Masahiro Yamawaki; Motoharu Araki; Norihiro Kobayashi; Shinsuke Mori; Masakazu Tsutsumi; Yosuke Honda; Keisuke Hirano; Yoshiaki Ito
Journal:  Heart Vessels       Date:  2019-04-08       Impact factor: 2.037

6.  Local Anti-miR Delivery: The Latest in the Arsenal of Drug-Eluting Stents.

Authors:  Kathryn J Moore; Katey J Rayner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09       Impact factor: 8.311

7.  Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation.

Authors:  Noha M Shawky; Lakshman Segar
Journal:  Pharmacol Res       Date:  2017-02-14       Impact factor: 7.658

Review 8.  Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment.

Authors:  Dario Buccheri; Davide Piraino; Giuseppe Andolina; Bernardo Cortese
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 9.  Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.

Authors:  Ron Waksman; Micaela Iantorno
Journal:  Curr Cardiol Rep       Date:  2018-10-22       Impact factor: 2.931

10.  Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.

Authors:  Farima Zahedi; Maliheh Nazari-Jahantigh; Zhe Zhou; Pallavi Subramanian; Yuanyuan Wei; Jochen Grommes; Stefan Offermanns; Sabine Steffens; Christian Weber; Andreas Schober
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.